Vertex, Mammoth partner to develop in vivo gene-editing therapies
Vertex Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo gene-editing therapies for two genetic diseases.
Page 3 - Peter Nell News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peter Nell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peter Nell Today - Breaking & Trending Today
Vertex, Mammoth Launch Up-to-$695M CRISPR Gene-Editing Collaboration
Vertex Pharmaceuticals will develop in vivo gene-editing therapies for two genetic diseases using Mammoth Biosciences’ CRISPR systems through a collaboration that could generate more than $695 million for Mammoth.
Source: genengnews.com